Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Rejection Chronic Renal

Interventions

DRUG: Belumosudil 200 mg QD
DRUG: Placebo

Sponsor

The Methodist Hospital Research Institute